SciClone Rises On Unusually High Volume (SCLN)

NEW YORK ( TheStreet) -- SciClone Pharmaceuticals (Nasdaq: SCLN) is trading at unusually high volume Friday with 2.2 million shares changing hands. It is currently at 4.4 times its average daily volume and trading up 28 cents (+4.2%) at $6.92 as of 4 p.m. ET.

SciClone has a market cap of $396.4 million and is part of the health care sector and drugs industry. Shares are up 62.7% year to date as of the close of trading on Thursday.

SciClone Pharmaceuticals, Inc. provides therapies for the treatment of oncology, infectious diseases, cardiovascular, urological, respiratory, and central nervous system disorders in the People's Republic of China and internationally. The company has a P/E ratio of 12.2, equal to the average drugs industry P/E ratio and below the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates SciClone as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow. You can view the full SciClone Ratings Report.

See all heavy volume stocks in our stocks moving on unusual volume list or get investment ideas from our investment research center.
null

If you liked this article you might like

Drug Price Inflation and a Patent Cliff Could Trigger a Wave of Deals in Generic Drugs Space

Drug Price Inflation and a Patent Cliff Could Trigger a Wave of Deals in Generic Drugs Space

Merck Up on Approval, Teva Sinks on Earnings and Asset Sales: Biotech Movers

Merck Up on Approval, Teva Sinks on Earnings and Asset Sales: Biotech Movers

Today's Weak On High Volume Stock: SciClone Pharmaceuticals (SCLN)

Today's Weak On High Volume Stock: SciClone Pharmaceuticals (SCLN)

SciClone Pharmaceuticals (SCLN): Today's Weak On High Volume Stock

SciClone Pharmaceuticals (SCLN): Today's Weak On High Volume Stock

Jim Cramer's 'Mad Money' Recap: Here's This Week's Game Plan

Jim Cramer's 'Mad Money' Recap: Here's This Week's Game Plan